Scholar Rock’s stock soars more than 200% on positive trial of treatment for spinal muscular atrophy
Scholar Rock Holdings Corp.’s stock soared more than 200% early Monday, after the clinical-stage biotech said a late-stage ...
Scholar Rock's Phase 3 SAPPHIRE Study Of Apitegromab In SMA Meets Primary Goal; Stock Surges
Scholar Rock Holding Corporation (SRRK), a late-stage biopharmaceutical company, Monday said its Phase 3 SAPPHIRE study evaluating ...
Scholar Rock shares triple after rare disease drug scores late-stage trial win
Scholar Rock said on Monday its experimental drug apitegromab met the main goal of a late-stage trial in patients with a type of rare genetic disease, sending the company's shares surging in premarket ...
Scholar Rock Holding's Spinal Muscular Atrophy Drug Apitegromab Meets Primary Study Endpoint
Scholar Rock Holding said that its treatment for spinal muscular atrophy met primary endpoint targets in a phase 3 clinical trial. The late-stage biopharmaceutical company said Monday that Apitegromab ...